Last reviewed · How we verify
NCT03573960
A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
Completed
Phase 4
Last updated 6 March 2026
What this trial tests
Phase 4 trial testing Lenvatinib in Thyroid Neoplasms in 50 participants. Completed in 4 September 2025.
Timeline
1 April 2018
Primary endpoint
4 September 2025
4 September 2025
4 September 2025
Quick facts
| Lead sponsor | Eisai Pharmaceuticals India Pvt. Ltd |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 April 2018 |
| Primary completion | 4 September 2025 |
| Estimated completion | 4 September 2025 |
| Sites | 11 locations across India |
Drugs / interventions tested
- Lenvatinib (LENVATINIB) — full drug profile →
Conditions studied
- Thyroid Neoplasms — all drugs for Thyroid Neoplasms →
Sponsor
Eisai Pharmaceuticals India Pvt. Ltd — full company profile →
Who can join
18 and older, any sex, with Thyroid Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the safety of lenvatinib in participants with recurrent, metastatic radio-iodine refractory differentiated thyroid cancer (DTC).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Updates on the Management of Thyroid Cancer.
Araque KA, Gubbi S, Klubo-Gwiezdzinska J. · · 2020 · cited 115× · PMID 32040962 · DOI 10.1055/a-1089-7870 -
New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression.
Bhatia S, Wang P, Toh A, Thompson EW. · · 2020 · cited 63× · PMID 32391381 · DOI 10.3389/fmolb.2020.00071 -
Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review.
Al-Jundi M, Thakur S, Gubbi S, Klubo-Gwiezdzinska J. · · 2020 · cited 56× · PMID 32751138 · DOI 10.3390/cancers12082104 -
Molecular features of aggressive thyroid cancer.
Elia G, Patrizio A, Ragusa F, Paparo SR, et al · · 2022 · cited 26× · PMID 36605433 · DOI 10.3389/fonc.2022.1099280 -
Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Cortas C, Charalambous H. · · 2023 · cited 7× · PMID 38255638 · DOI 10.3390/life14010022 -
Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer.
Herranz UA. · · 2022 · cited 3× · PMID 36202606 · DOI 10.1002/cam4.5105 -
Natural Killer Cell-Mediated Antitumor Immunity: Molecular Mechanisms and Clinical Applications.
Luo N, Chen C, Zhou W, Hao J, et al · · 2025 · cited 2× · PMID 40959206 · DOI 10.1002/mco2.70387 -
Leveraging molecular targeted drugs and immune checkpoint inhibitors treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation.
Su JY, Huang T, Zhang JL, Lu JH, et al · · 2024 · cited 1× · PMID 38455407 · DOI 10.62347/ejaa3388
Verify or expand the search:
- PubMed search for NCT03573960
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lenvatinib
Trials testing the same drug.
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
- NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
- NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
- NCT07518706 — Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin · Phase 2 · not yet recruiting
- NCT07493668 — Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy · Phase 2 · not yet recruiting
Other recruiting trials for Thyroid Neoplasms
Currently open trials in the same condition.
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
- NCT07447089 — EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study · NA · recruiting
- NCT07010380 — Dual-Channel Near-Infrared Autofluorescence Imaging and AI Analysis to Locate Parathyroid Glands (PTFinder) · recruiting
- NCT07434206 — Safety and Efficacy of Dexmedetomidine in Controlling Hemodynamics During Resection of Active Thyroid Secreting Tumors · Phase 2, PHASE3 · active not recruiting
- NCT06398795 — Dual-port Trans-subclavian Thyroid Endoscopic Surgery · NA · recruiting
Other Eisai Pharmaceuticals India Pvt. Ltd trials
Trials by the same sponsor.
- NCT04297254 — A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC · Phase 4 · completed
- NCT03836924 — A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset S · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03573960 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eisai Pharmaceuticals India Pvt. Ltd
- Last refreshed: 6 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03573960.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing